Researchers of a study found that dupilumab treatment significantly reduces the risk of atopic march progression in pediatric and adolescent patients with atopic dermatitis (AD). The retrospective cohort study compared 2,192 pediatric patients newly treated with dupilumab to an equal number of patients receiving conventional therapies. Results showed that the 3-year cumulative incidence of atopic march progression was significantly lower in the dupilumab group (20.09%) compared with the conventional therapy group (27.22%). Dupilumab also reduced the risk of developing asthma and allergic rhinitis, particularly in younger children, with preschool-aged children seeing the greatest benefit in asthma risk reduction.

The study highlighted that patients treated with dupilumab had a lower risk of atopic march progression across all age groups, including preschoolers, school-aged children, and adolescents. Researchers recommended further research with extended follow-up to confirm these results and better understand the long-term effects of dupilumab treatment.

Reference: Grasso G. Dupilumab associated with reduced risk for atopic march progression. Healio. Published July 08, 2024. Accessed September 19, 2024. https://www.healio.com/news/dermatology/20240708/dupilumab-associated-with-reduced-risk-for-atopic-march-progression?utm_source=selligent&utm_medium=email&utm_campaign=news